title: Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats.
abstract: Trihexyphenidyl (THP) is a drug commonly used to reduce parkinsonian symptoms. An important side effect of this agent is memory impairment. Since caffeine enhances the potency of THP to inhibit haloperidol-induced catalepsy, caffeine may be used as an adjuvant of lower doses of THP, in order to improve its antiparkinsonian effects without causing memory disruption. To further assess the synergism between caffeine and THP, both drugs were tested in reserpinized rats, another preclinical model of Parkinson's disease. Four groups of rats (n = 7) were treated with reserpine (5 mg/kg, i.p.). A control group (n = 7) was treated only with the vehicle for reserpine (dimethylsulphoxide). The spontaneous locomotor behavior was tested 24 h later in a box with infrared sensors, 30 min after receiving one of the following treatments: distilled water (1 ml/kg), caffeine (1 mg/kg), THP (0.1 mg/kg) or caffeine plus THP. The levels of horizontal locomotion (14 +/- 5%) and vertical exploration (15 +/- 10%) were significantly lower in reserpinized rats treated with distilled water, compared with the mean activity values (100%) recorded in animals pretreated only with the vehicle for reserpine. The reserpine-induced hypokinesia was neither reversed by caffeine alone nor by THP alone. However, the combination of caffeine plus THP restored locomotion (141 +/- 19%) and vertical exploration (82 +/- 17%) to levels not significantly different to those of non-reserpinized rats. Moreover, the time-course of locomotion and exploration displayed the characteristic habituation over time, in which short-term memory processes are involved. Also, the thigmotaxis index indicated that the combined treatment did not induce anxiety-like behavior. Hence, these results support the proposal that low, subthreshold doses of caffeine plus THP have the potential to alleviate the motor disabilities in parkinsonian patients, with a low risk of causing anxiety or memory impairment.
authors.affiliation: Laboratorio de Neurofisiología, Departamento de Neurociencias, Centro de Investigaciones Regionales Dr Hideyo Noguchi, Universidad Autónoma de Yucatán, Avenida Itzáes No. 490, Mérida, 97000, Mexico.
authors.forename: Rosa E
authors.initials: RE
authors.lastname: Moo-Puc
authors.forename: Jairo
authors.initials: J
authors.lastname: Villanueva-Toledo
authors.forename: Gloria
authors.initials: G
authors.lastname: Arankowsky-Sandoval
authors.forename: Fernando
authors.initials: F
authors.lastname: Alvarez-Cervera
authors.forename: José L
authors.initials: JL
authors.lastname: Góngora-Alfaro
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002110:Caffeine / Q000494:pharmacology / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004347:Drug Interactions; D005106:Exploratory Behavior / Q000187:drug effects*; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology; D051381:Rats; D017208:Rats, Wistar; D012110:Reserpine / Q000009:adverse effects; D014282:Trihexyphenidyl / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000697:Central Nervous System Stimulants; D002110:Caffeine; D014282:Trihexyphenidyl; D012110:Reserpine